Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No New Clinical Or Safety Concerns Cited

Loading news article.

Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No New Clinical Or Safety Concerns Cited | WAPE

Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No New Clinical Or Safety Concerns Cited

Article summary

Related companies

Comments —